Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?

Annals of Nuclear Medicine

Volumn 26, Issue 7, 2012, Pages 571-577

  Yang, Zhongyi ^a,b   Cheng, Jingyi ^a,b   Pan, Lingling ^a,b   Hu, Silong ^a,b   Xu, Junyan ^a,b   Zhang, Yongping ^a,b   Wang, Mingwei ^a,b   Zhang, Jianping ^a,b   Ye, Dingwei ^a,b   Zhang, Yingjian ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Bladder cancer; Fluorine 18 fluorodeoxyglucose; Positron emission tomography computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER WALL; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYSTOSCOPE; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYDRATION; INFLAMMATION; MALE; MICTURITION; PELVIS RADIOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PELVIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; URINARY BLADDER; URINARY BLADDER NEOPLASMS; WHOLE BODY IMAGING;

EID: 84866732095     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0614-3     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54:303-14.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-77.
4. Van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in nonmuscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56:430-42.
5. Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163:1693-6.
6. Yaman O, Baltaci S, Arikan N, Yilmaz E, Gögüs O. Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma. Br J Urol. 1996;78: 197-200.
7. Baltaci S, Resorlu B, Yagci C, Turkolmez K, Gogus C, Beduk Y. Computerized tomography for detecting perivesical infiltration and lymph node metastasis in invasive bladder carcinoma. Urol Int. 2008;81:399-402.
8. Podoloff DA, Ball DW, Ben-Josef E, Benson AB 3rd, Cohen SJ, Coleman RE, et al. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Cancer Netw. 2009;7: S1-26.
9. Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005;32:1412-7.
10. Apolo AB, Riches J, Schöder H, Akin O, Trout A, Milowsky MI, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010;28:3973-8.
11. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med. 1997;24:615-20.
12. Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med. 2007;48:764-70.
13. Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int. 2010;106:658-63.
14. Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009;27: 4314-20.
15. Liu IJ, Lai YH, Espiritu JI, Segall GM, Srinivas S, Nino-Murcia M, et al. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int. 2006;77:69-75.
16. Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K, et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 2010;57:641-7.
17. Jadvar H, Quan V, Henderson RW, Conti PS. [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol. 2008;13:42-7.
18. Heicappell R, Müller-Mattheis V, Reinhardt M, Vosberg H, Gerharz CD, Müller-Gärtner H, et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol. 1999;36:582-7.
19. Weissleder R. Molecular imaging in cancer. Science. 2006;312:1168-71.
20. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology. 2007;244: 39-47.
21. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006;57: 99-118.
22. Jager PL, de Korte MA. Lub-de Hooge MN, van Waarde A, Koopmans KP, Perik PJ, et al. Molecular imaging: what can be used today. Cancer Imaging. 2005;5:S27-32.
23. Patil VV, Wang ZJ, Sollitto RA, Chuang KW, Konety BR, Hawkins RA, et al. 18F-FDG PET/CT of transitional cell carcinoma. AJR Am J Roentgenol. 2009;193:W497-504.
24. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511-20.
25. Lin WY, Wang KB, Tsai SC, Sun SS. Unexpected accumulation of F-18 FDG in the urinary bladder after bladder irrigation and retrograde filling with sterile saline: a possible pitfall in PET examination. Clin Nucl Med. 2009;34:560-3.
26. Nijjar S, Patterson J, Ducharme J, Leslie WD, Demeter SJ. The effect of furosemide dose timing on bladder activity in oncology imaging with 18F-fluorodeoxyglucose PET/CT. Nucl Med Commun. 2010;31:167-72.
27. Kumar K. Settlement of [l8F]-FDG in the urinary bladder-a new sign. Nucl Med Commun. 2009;30:37-40.
28. Purcell DD, Coakley FV, Franc BL, Hawkins RA, Boddington SE, Yeh BM. Anterior layering of excreted 18F-FDG in the bladder on PET/CT: frequency and cause. AJR Am J Roentgenol. 2007;189:W96-9.